Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs?

ETHNOPHARMACOLOGICAL RELEVANCE A wealth of information is emerging about the impact of gut microbiota on human health and diseases such as cardiovascular diseases, obesity and diabetes. As we learn more, we find out the gut microbiota has the potential as new territory for drug targeting. Some novel therapeutic approaches could be developed through reshaping the commensal microbial structure using combinations of different agents. The gut microbiota also affects drug metabolism, directly and indirectly, particularly towards the orally administered drugs. Herbal products have become the basis of traditional medicines such as traditional Chinese medicine and also been being considered valuable materials in modern drug discovery. Of note, low oral bioavailability but high bioactivity is a conundrum not yet solved for some herbs. Since most of herbal products are orally administered, the herbs' constituents are inevitably exposed to the intestinal microbiota and the interplays between herbal constituents and gut microbiota are expected. Emerging explorations of herb-microbiota interactions have an opportunity to revolutionize the way we view herbal therapeutics. The present review aims to provide information regarding the health promotion and/or disease prevention by the interplay between traditional herbs with low bioavailability and gut microbiota through gut microbiota via two different types of mechanisms: (1) influencing the composition of gut microbiota by herbs and (2) metabolic reactions of herbal constituents by gut microbiota. MATERIALS AND METHODS The major data bases (PubMed and Web of Science) were searched using "gut microbiota", "intestinal microbiota", "gut flora", "intestinal flora", "gut microflora", "intestinal microflora", "herb", "Chinese medicine", "traditional medicine", or "herbal medicine" as keywords to find out studies regarding herb-microbiota interactions. The Chinese Pharmacopoeia (2010 edition, Volume I) was also used to collect the data of commonly used medicinal herbs and their quality control approaches. RESULTS Among the 474 monographs of herbs usually used in the Chinese Pharmacopoeia, the quality control approach of 284 monographs is recommended to use high-performance liquid chromatography approach. Notably, the major marker compounds (>60%) for quality control are polyphenols, polysaccharides and saponins, with significant oral bioavailability conundrum. Results from preclinical and clinical studies on herb-microbiota interactions showed that traditional herbs could exert heath promotion and disease prevention roles via influencing the gut microbiota structure. On the other hand, herb constituents such as ginsenoside C-K, hesperidin, baicalin, daidzin and glycyrrhizin could exert their therapeutic effects through gut microbiota-mediated bioconversion. CONCLUSIONS Herb-microbiota interaction studies provide novel mechanistic understanding of the traditional herbs that exhibit poor oral bioavailability. "Microbiota availability" could be taken consideration into describing biological measurements in the therapeutic assessment of herbal medicine. Our review should be of value in stimulating discussions among the scientific community on this relevant theme and prompting more efforts to complement herb-microbiota interactions studies.

[1]  K. Pearson,et al.  Resveratrol and cancer: focus on in vivo evidence , 2014, Endocrine-related cancer.

[2]  Y. Kashiwada,et al.  Hepatoprotective effect of fermented ginseng and its major constituent compound K in a rat model of paracetamol (acetaminophen)‐induced liver injury , 2015, The Journal of pharmacy and pharmacology.

[3]  Liping Zhao,et al.  Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats , 2015, Scientific Reports.

[4]  Y. Naito,et al.  Relationships among fecal daidzein metabolites, dietary habit and BMI in healthy volunteers: a preliminary study , 2015, Bioscience of microbiota, food and health.

[5]  F. Cheung TCM: Made in China , 2011, Nature.

[6]  P. Smith The tantalizing links between gut microbes and the brain , 2015, Nature.

[7]  Junling Han,et al.  Modulating gut microbiota as an anti-diabetic mechanism of berberine , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[8]  S. Raimondi,et al.  Hydrolysis of the Rutinose-Conjugates Flavonoids Rutin and Hesperidin by the Gut Microbiota and Bifidobacteria , 2015, Nutrients.

[9]  M. Fraga,et al.  The effects of the dietary polyphenol resveratrol on human healthy aging and lifespan , 2011, Epigenetics.

[10]  Xiao Lin,et al.  A sensitive and specific HPGPC-FD method for the study of pharmacokinetics and tissue distribution of Radix Ophiopogonis polysaccharide in rats. , 2009, Biomedical chromatography : BMC.

[11]  Miyoung Song,et al.  Influence of Panax ginseng on obesity and gut microbiota in obese middle-aged Korean women , 2014, Journal of ginseng research.

[12]  Wei-Jia Kong,et al.  Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. , 2010, Metabolism: clinical and experimental.

[13]  T. H. Huang,et al.  Chemistry and Pharmacology of Gynostemma pentaphyllum , 2005, Phytochemistry Reviews.

[14]  Y. Ming,et al.  Compound K-induced apoptosis of human hepatocellular carcinoma MHCC97-H cells in vitro. , 2014, Oncology reports.

[15]  M. Motilva,et al.  Bioavailability of procyanidin dimers and trimers and matrix food effects in in vitro and in vivo models. , 2010, The British journal of nutrition.

[16]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[17]  Hyung-Gu Kim,et al.  Fermented Rhizoma Atractylodis Macrocephalae alleviates high fat diet-induced obesity in association with regulation of intestinal permeability and microbiota in rats , 2015, Scientific Reports.

[18]  K. Ruan,et al.  Effect of MDG-1 on oral glucose tolerance and intestinal microecological balance in diabetic mice , 2011 .

[19]  S. Dowd,et al.  Effects of polysaccharopeptide from Trametes Versicolor and amoxicillin on the gut microbiome of healthy volunteers , 2014, Gut microbes.

[20]  Christoph H Borchers,et al.  Metabolomics: towards understanding host-microbe interactions. , 2010, Future microbiology.

[21]  Ru Yan,et al.  The Presystemic Interplay between Gut Microbiota and Orally Administered Calycosin-7-O-β-d-Glucoside , 2015, Drug Metabolism and Disposition.

[22]  S. Granica,et al.  Extracts from Epilobium sp. Herbs, Their Components and Gut Microbiota Metabolites of Epilobium Ellagitannins, Urolithins, Inhibit Hormone‐Dependent Prostate Cancer Cells‐(LNCaP) Proliferation and PSA Secretion , 2013, Phytotherapy research : PTR.

[23]  Daniel Kolarich,et al.  The role of glycosylation in IBD , 2014, Nature Reviews Gastroenterology &Hepatology.

[24]  Larry L. Constantine,et al.  Back to the future , 2001, CACM.

[25]  M. Blaser,et al.  The human microbiome: at the interface of health and disease , 2012, Nature Reviews Genetics.

[26]  T. Clavel,et al.  Phenolics in Human Nutrition: Importance of the Intestinal Microbiome for Isoflavone and Lignan Bioavailability 78 , 2013 .

[27]  D. Barron,et al.  In Vivo Bioavailability, Absorption, Excretion, and Pharmacokinetics of [14C]Procyanidin B2 in Male Rats , 2010, Drug Metabolism and Disposition.

[28]  E. Mardis,et al.  An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.

[29]  K. Kobashi,et al.  Drug Metabolism: Intestinal Bacterial Hydrolysis is Required for the Appearance of Compound K in Rat Plasma after Oral Administration of Ginsenoside Rb1 from Panax ginseng , 1998 .

[30]  Ki-Choon Choi,et al.  Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. , 2005, Endocrinology.

[31]  A. Falcão,et al.  Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. , 2009, Molecular nutrition & food research.

[32]  F. A. Macias,et al.  Soy isoflavones and their relationship with microflora: beneficial effects on human health in equol producers , 2013, Phytochemistry Reviews.

[33]  D. Sliva,et al.  ReishiMax, mushroom based dietary supplement, inhibits adipocyte differentiation, stimulates glucose uptake and activates AMPK , 2011, BMC complementary and alternative medicine.

[34]  Xin Wang,et al.  Cancer prevention by tea: animal studies, molecular mechanisms and human relevance , 2009, Nature Reviews Cancer.

[35]  Feng Chen,et al.  Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administration , 2013, British journal of pharmacology.

[36]  Shusen Zheng,et al.  Application of metagenomics in the human gut microbiome. , 2015, World journal of gastroenterology.

[37]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[38]  Sang-Min Lee,et al.  Effects of Atractylodes macrocephala Koidzumi rhizome on 3T3-L1 adipogenesis and an animal model of obesity. , 2011, Journal of ethnopharmacology.

[39]  The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. , 2015, Molecular nutrition & food research.

[40]  D. Ilstrup,et al.  A Double-blind, Placebo-Controlled Study , 2017 .

[41]  W. Tai,et al.  Tumor Grafting Induces Changes of Gut Microbiota in Athymic Nude Mice in the Presence and Absence of Medicinal Gynostemma Saponins , 2015, PloS one.

[42]  Gabriel Núñez,et al.  Control of pathogens and pathobionts by the gut microbiota , 2013, Nature Immunology.

[43]  Sang-Uk Seo,et al.  Role of the gut microbiota in immunity and inflammatory disease , 2013, Nature Reviews Immunology.

[44]  Feng Chen,et al.  Absorption, disposition, and pharmacokinetics of saponins from Chinese medicinal herbs: what do we know and what do we need to know more? , 2012, Current drug metabolism.

[45]  A. Braune,et al.  Daidzein and genistein are converted to equol and 5-hydroxy-equol by human intestinal Slackia isoflavoniconvertens in gnotobiotic rats. , 2012, The Journal of nutrition.

[46]  F. Milagro,et al.  Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. , 2015, The Journal of nutritional biochemistry.

[47]  J. Vincken,et al.  Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-gamma-valerolactone as the major metabolites. , 2009, Journal of agricultural and food chemistry.

[48]  Lian‐Wen Qi,et al.  Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides. , 2011, The American journal of Chinese medicine.

[49]  M. Jutila,et al.  Oenothein B, a Cyclic Dimeric Ellagitannin Isolated from Epilobium angustifolium, Enhances IFNγ Production by Lymphocytes , 2012, PloS one.

[50]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[51]  H. Flint,et al.  Role of the gut microbiota in nutrition and health , 2018, British Medical Journal.

[52]  Wei Wei,et al.  Ginsenoside Metabolite Compound K Suppresses T-Cell Priming via Modulation of Dendritic Cell Trafficking and Costimulatory Signals, Resulting in Alleviation of Collagen-Induced Arthritis , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[53]  Wentao Xu,et al.  Red Ginseng and Semen Coicis can improve the structure of gut microbiota and relieve the symptoms of ulcerative colitis. , 2015, Journal of ethnopharmacology.

[54]  K. Kang,et al.  Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity. , 2013, International journal of oncology.

[55]  S. Moon,et al.  Metabolic activities of ginsenoside Rb1, baicalin, glycyrrhizin and geniposide to their bioactive compounds by human intestinal microflora. , 2004, Biological & pharmaceutical bulletin.

[56]  T. Walle Bioavailability of resveratrol , 2011, Annals of the New York Academy of Sciences.

[57]  J. Clemente,et al.  The Impact of the Gut Microbiota on Human Health: An Integrative View , 2012, Cell.

[58]  Yu-Hui Liu,et al.  Anti-diabetic activities of Gegen Qinlian Decoction in high-fat diet combined with streptozotocin-induced diabetic rats and in 3T3-L1 adipocytes. , 2013, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[59]  F. Vaillant,et al.  Metabolic Fate of Ellagitannins: Implications for Health, and Research Perspectives for Innovative Functional Foods , 2014, Critical reviews in food science and nutrition.

[60]  R. Verpoorte Good practices: the basis for evidence-based medicines. , 2012, Journal of ethnopharmacology.

[61]  Xiumei Gao,et al.  Absorption and Disposition of Ginsenosides after Oral Administration of Panax notoginseng Extract to Rats , 2009, Drug Metabolism and Disposition.

[62]  W. Xie,et al.  Effects and Action Mechanisms of Berberine and Rhizoma coptidis on Gut Microbes and Obesity in High-Fat Diet-Fed C57BL/6J Mice , 2011, PloS one.

[63]  Liping Zhao,et al.  Whole-body systems approaches for gut microbiota-targeted, preventive healthcare. , 2010, Journal of biotechnology.

[64]  Xiao Chen,et al.  The role of gut microbiota in the gut-brain axis: current challenges and perspectives , 2013, Protein & Cell.

[65]  W. Jung,et al.  Biotransformation of ginsenoside Rb1, crocin, amygdalin, geniposide, puerarin, ginsenoside Re, hesperidin, poncirin, glycyrrhizin, and baicalin by human fecal microflora and its relation to cytotoxicity against tumor cells. , 2008, Journal of microbiology and biotechnology.

[66]  Harry J. Flint,et al.  The gut microbiota, bacterial metabolites and colorectal cancer , 2014, Nature Reviews Microbiology.

[67]  S. Mazmanian,et al.  The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.

[68]  Michael E Phelps,et al.  Systems Biology and New Technologies Enable Predictive and Preventative Medicine , 2004, Science.

[69]  Andrea P. Clavijo,et al.  Fecal Bacterial Community Changes Associated with Isoflavone Metabolites in Postmenopausal Women after Soy Bar Consumption , 2014, PloS one.

[70]  Y. Benno,et al.  Effects of green tea consumption on human fecal microbiota with special reference to Bifidobacterium species , 2012, Microbiology and immunology.

[71]  I. Bae,et al.  Fermented green tea extract alleviates obesity and related complications and alters gut microbiota composition in diet-induced obese mice. , 2015, Journal of medicinal food.

[72]  S. Ahrné,et al.  Green tea powder and Lactobacillus plantarum affect gut microbiota, lipid metabolism and inflammation in high-fat fed C57BL/6J mice , 2012, Nutrition & Metabolism.

[73]  W. Chung,et al.  Effect of Korean Herbal Medicine Combined with a Probiotic Mixture on Diarrhea-Dominant Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Trial , 2013, Evidence-based complementary and alternative medicine : eCAM.

[74]  Miyoung Song,et al.  The anti-obesity effect of Ephedra sinica through modulation of gut microbiota in obese Korean women. , 2014, Journal of ethnopharmacology.

[75]  M. Melzig,et al.  Role of human gut microbiota metabolism in the anti-inflammatory effect of traditionally used ellagitannin-rich plant materials. , 2014, Journal of ethnopharmacology.

[76]  Shobha Bhattachar,et al.  The road map to oral bioavailability: an industrial perspective , 2006, Expert opinion on drug metabolism & toxicology.

[77]  V. Somoza,et al.  Metabolism and bioavailability of trans-resveratrol. , 2005, Molecular nutrition & food research.

[78]  Kaixian Chen,et al.  Immunosuppressive Effects of A-Type Procyanidin Oligomers from Cinnamomum tamala , 2014, Evidence-based complementary and alternative medicine : eCAM.

[79]  F. Tinahones,et al.  Benefits of polyphenols on gut microbiota and implications in human health. , 2013, The Journal of nutritional biochemistry.

[80]  M. Li,et al.  Structural Changes of Gut Microbiota during Berberine-Mediated Prevention of Obesity and Insulin Resistance in High-Fat Diet-Fed Rats , 2012, PloS one.

[81]  P. M. Or,et al.  Metabolite profiling analysis of FR429, an ellagitannin purified from Polygonum capitatum, in rat and human liver microsomes, cytosol and rat primary hepatocytes in vitro. , 2014, Chemico-biological interactions.

[82]  K. Kobashi,et al.  Balicalin, the Predominant Flavone Glucuronide of Scutellariae Radix, is Absorbed from the Rat Gastrointestinal Tract as the Aglycone and Restored to its Original Form , 2000, The Journal of pharmacy and pharmacology.

[83]  J. Lundberg,et al.  An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants : APG II THE ANGIOSPERM PHYLOGENY GROUP * , 2003 .

[84]  Jae-Woo Park,et al.  Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial , 2011, Trials.

[85]  Miyoung Song,et al.  Schisandra chinensis fruit modulates the gut microbiota composition in association with metabolic markers in obese women: a randomized, double-blind placebo-controlled study. , 2015, Nutrition research.

[86]  M. Icaza-Chávez,et al.  Gut microbiota in health and disease , 2013 .

[87]  J. Pezzuto,et al.  What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol , 2011, PloS one.

[88]  L. Ding,et al.  Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. , 2007, Journal of pharmaceutical and biomedical analysis.

[89]  Xuewu Zhang,et al.  Lentinula edodes-Derived Polysaccharide Alters the Spatial Structure of Gut Microbiota in Mice , 2015, PloS one.

[90]  H. Jeong,et al.  Role of metabolism by intestinal microbiota in pharmacokinetics of oral baicalin , 2014, Archives of pharmacal research.

[91]  J. Neuzil,et al.  Mitocans, a class of emerging anti-cancer drugs. , 2009, Molecular nutrition & food research.

[92]  Raju V. Misra,et al.  Challenges of the Unknown: Clinical Application of Microbial Metagenomics , 2015, International journal of genomics.

[93]  S. Delgado,et al.  Equol status and changes in fecal microbiota in menopausal women receiving long-term treatment for menopause symptoms with a soy-isoflavone concentrate , 2015, Front. Microbiol..

[94]  A. Falcão,et al.  Pharmacokinetics of Trans‐resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects , 2009, Journal of clinical pharmacology.

[95]  P. Brigidi,et al.  Metagenomics: Key to Human Gut Microbiota , 2011, Digestive Diseases.

[96]  Dayong Ren,et al.  Effects of compound K on hyperglycemia and insulin resistance in rats with type 2 diabetes mellitus. , 2014, Fitoterapia.

[97]  F. Shanahan,et al.  The gut flora as a forgotten organ , 2006, EMBO reports.

[98]  R. Kedzierski,et al.  Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[99]  G. Ning,et al.  Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. , 2008, The Journal of clinical endocrinology and metabolism.

[100]  D. Goldberg,et al.  Absorption of three wine-related polyphenols in three different matrices by healthy subjects. , 2003, Clinical biochemistry.

[101]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[102]  David C. Tank,et al.  An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants: , 2009 .

[103]  J. Piwowarski,et al.  In vitro antioxidant and anti-inflammatory activities of extracts from Potentilla recta and its main ellagitannin, agrimoniin. , 2013, Journal of ethnopharmacology.

[104]  P. Zhou,et al.  Antidiabetic, Antihyperlipidemic and Antioxidant Activities of a Novel Proteoglycan from Ganoderma Lucidum Fruiting Bodies on db/db Mice and the Possible Mechanism , 2013, PloS one.

[105]  Mathieu Almeida,et al.  Dietary intervention impact on gut microbial gene richness , 2013, Nature.

[106]  C. Huh,et al.  Comparative Analysis of the Gut Microbiota in People with Different Levels of Ginsenoside Rb1 Degradation to Compound K , 2013, PloS one.

[107]  F. Lombó,et al.  Bioavailability of Dietary Polyphenols and Gut Microbiota Metabolism: Antimicrobial Properties , 2015, BioMed research international.

[108]  Xi Chen,et al.  Transforming berberine into its intestine-absorbable form by the gut microbiota , 2015, Scientific Reports.

[109]  Li Taiming,et al.  Investigation of the absorption mechanisms of baicalin and baicalein in rats. , 2006, Journal of pharmaceutical sciences.

[110]  Jing-Hua Wang,et al.  Flos Lonicera Ameliorates Obesity and Associated Endotoxemia in Rats through Modulation of Gut Permeability and Intestinal Microbiota , 2014, PloS one.

[111]  D. Newburg,et al.  Trametes versicolor Extract Modifies Human Fecal Microbiota Composition In vitro , 2013, Plant Foods for Human Nutrition.

[112]  Y. Ishimi,et al.  Effects of short-term fructooligosaccharide intake on equol production in Japanese postmenopausal women consuming soy isoflavone supplements: a pilot study , 2013, Nutrition Journal.

[113]  Chih-Jung Chang,et al.  Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota , 2015, Nature Communications.

[114]  D. Noble,et al.  Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.

[115]  Guangji Wang,et al.  Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. , 2009, Journal of pharmaceutical sciences.

[116]  G. D. Pimentel,et al.  Green Tea Extract Supplementation Induces the Lipolytic Pathway, Attenuates Obesity, and Reduces Low-Grade Inflammation in Mice Fed a High-Fat Diet , 2013, Mediators of inflammation.

[117]  P. Langella,et al.  The role of metagenomics in understanding the human microbiome in health and disease , 2014, Virulence.

[118]  J. Parkhill,et al.  Fighting Obesity with Bacteria , 2013, Science.

[119]  Elaine Holmes,et al.  Targeting the human genome-microbiome axis for drug discovery: inspirations from global systems biology and traditional Chinese medicine. , 2012, Journal of proteome research.

[120]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[121]  A. Schäfer,et al.  An ellagitannin, n-butyl gallate, two aryltetralin lignans, and an unprecedented diterpene ester from Pelargonium reniforme. , 2008, Phytochemistry.

[122]  D. Barron,et al.  A comparison of the in vitro biotransformation of (-)-epicatechin and procyanidin B2 by human faecal microbiota. , 2010, Molecular nutrition & food research.

[123]  Liping Zhao The gut microbiota and obesity: from correlation to causality , 2013, Nature Reviews Microbiology.

[124]  M. Quon,et al.  New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate , 2014, Redox biology.

[125]  M. Garcia-Conesa,et al.  Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence , 2013, Current pharmaceutical design.

[126]  P. Cordero,et al.  Whole‐Genome Sequencing in Personalized Therapeutics , 2012, Clinical pharmacology and therapeutics.

[127]  Jin-Ling Tang,et al.  Research priorities in traditional Chinese medicine , 2006, BMJ : British Medical Journal.

[128]  L. Gu,et al.  Microbial catabolism of procyanidins by human gut microbiota. , 2014, Molecular nutrition & food research.

[129]  D. Mereles,et al.  Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? , 2011, International journal of molecular sciences.

[130]  Y. Song,et al.  Anti‐angiogenic, antinociceptive and anti‐inflammatory activities of Lonicera japonica extract , 2008, The Journal of pharmacy and pharmacology.

[131]  Xuewu Zhang,et al.  Structure and immuno-stimulating activities of a new heteropolysaccharide from Lentinula edodes. , 2012, Journal of agricultural and food chemistry.

[132]  Y. Wang,et al.  MDG-1, an Ophiopogon polysaccharide, regulate gut microbiota in high-fat diet-induced obese C57BL/6 mice. , 2015, International journal of biological macromolecules.

[133]  Guangji Wang,et al.  Pharmacokinetic and absolute bioavailability study of total panax notoginsenoside, a typical multiple constituent traditional chinese medicine (TCM) in rats. , 2007, Biological & pharmaceutical bulletin.